Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4584815
Max Phase: Preclinical
Molecular Formula: C36H41FN4O9
Molecular Weight: 692.74
Molecule Type: Unknown
Associated Items:
ID: ALA4584815
Max Phase: Preclinical
Molecular Formula: C36H41FN4O9
Molecular Weight: 692.74
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=C1C(=O)O[C@H]2[C@H]1CC/C(COC(=O)CCC(=O)N1CCN(C(=O)Cn3cc(F)c(=O)n(Cc4ccccc4)c3=O)CC1)=C\CC[C@@]1(C)O[C@@H]21
Standard InChI: InChI=1S/C36H41FN4O9/c1-23-26-11-10-25(9-6-14-36(2)32(50-36)31(26)49-34(23)46)22-48-30(44)13-12-28(42)38-15-17-39(18-16-38)29(43)21-40-20-27(37)33(45)41(35(40)47)19-24-7-4-3-5-8-24/h3-5,7-9,20,26,31-32H,1,6,10-19,21-22H2,2H3/b25-9+/t26-,31-,32-,36+/m0/s1
Standard InChI Key: VLJPJZMKUPRCGK-ZQIHOFEQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 692.74 | Molecular Weight (Monoisotopic): 692.2858 | AlogP: 1.95 | #Rotatable Bonds: 9 |
Polar Surface Area: 149.75 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 0 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 1.99 | CX LogD: 1.99 |
Aromatic Rings: 2 | Heavy Atoms: 50 | QED Weighted: 0.17 | Np Likeness Score: 0.52 |
1. Ding Y, Li S, Ge W, Liu Z, Zhang X, Wang M, Chen T, Chen Y, Zhang Q.. (2019) Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma., 183 [PMID:31553932] [10.1016/j.ejmech.2019.111706] |
Source(1):